FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 813 participants.
Also called NCT03276143
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 2
- Enrolled
- 813 participants
- Sponsor
- Registry
-
NCT03276143 -
2016-002681-31
-
- Other papers using this trial's data
- Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Bulgaria, Canada, Czechia, Greece, Israel, Latvia, Lithuania, Poland, Portugal, Russia, South Africa, Spain, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT03276143. Randomized; quadruple masking; primary purpose prevention. Start 2017-09-21 (actual); primary completion 2018-08-20 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty
- Acronym
- FOXTROT
- Condition
- Knee Arthroplasty, Total
- Intervention (Drug)
- Enoxaparin
- Intervention (Drug)
- Apixaban
- Intervention (Drug)
- BAY1213790
- Lead sponsor
- Bayer
Record details
- Record id
cardio:ct-nct03276143- Content hash
8c29bbbe6f1147633922450b20402b5ec8abee82a1f4a4dd9f7eea37ea5a57ee